AB Science S.A. (ABSCF)
| Previous close | 10.60 |
| Open | 10.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 10.60 - 10.60 |
| 52-week range | 10.60 - 18.78 |
| Volume | |
| Avg. volume | 9 |
| Market cap | 496.73M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy
PRESS RELEASE AB SCIENCE ANNOUNCES PUBLICATION IN THE JOURNAL OF ASTHMA AND ALLERGY OF POSITIVE MASITINIB PHASE 3 CLINICAL TRIAL RESULTS IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA Paris, 7 June, 2022, 5.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy [1]. This article, titled ‘Efficacy an
- Globe Newswire
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS STARTED THE REVIEW OF NEW DRUG SUBMISSION FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS), FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE LETTER Paris, 26 May, 2022, 10pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), meaning that the information and mat
- Globe Newswire
AB Science reports its revenues for the year 2021 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2021 AND THE KEY EVENTS OF THE PERIOD Clinical development Authorization by Health Canada to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis under the NOC/c policyPublication of new long-term data showing that masitinib extended survival in amyotrophic lateral sclerosis by 25 months, provided that treatment starts early in disease courseContinuation of the development program
